Guilford Pharmaceuticals Inc. – Trademark Portfolio

Entity Type: 03

Guilford Pharmaceuticals Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. The owner is based in Baltimore, MD.

6611 Tributary Street

Baltimore, MD 21224

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Guilford Pharmaceuticals Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

36
Insurance & Financial (1 filing)

Insurance; financial affairs; monetary affairs; real estate affairs

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Guilford Pharmaceuticals Inc. have?

Guilford Pharmaceuticals Inc. has 10 U.S. trademarks filed with the USPTO.

What trademark classes does Guilford Pharmaceuticals Inc. file in?

Guilford Pharmaceuticals Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is Guilford Pharmaceuticals Inc.'s trademark registration success rate?

Guilford Pharmaceuticals Inc. has a 0% trademark registration rate, with 0 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.